Outcome of PCI with Xience versus other commonly used modern drug eluting stents : A SCAAR report
(2021) In Catheterization and Cardiovascular Interventions 98(2).- Abstract
Objectives: To analyze the clinical outcome of percutaneous coronary intervention (PCI) using the Xience drug eluting stent (DES) versus other modern DES. Methods: This retrospective study based on the Swedish Coronary Angiography and Angioplasty Registry (SCAAR) analyzed the outcome of PCI using Xience versus other commonly used modern DES, 2007 to 2017. The primary outcome measure was a combination of all-cause death, myocardial infarction (MI) and revascularisation with PCI. Angiographical outcome measures were in-stent restenosis (ISR) and stent thrombosis (ST). Results: Rates of the primary outcome measure for Xience and other DES were 31.9% and 28.2% respectively, adjusted hazard ratio (HR) 0.99 (95% CI 0.95–1.03). Crude rates of... (More)
Objectives: To analyze the clinical outcome of percutaneous coronary intervention (PCI) using the Xience drug eluting stent (DES) versus other modern DES. Methods: This retrospective study based on the Swedish Coronary Angiography and Angioplasty Registry (SCAAR) analyzed the outcome of PCI using Xience versus other commonly used modern DES, 2007 to 2017. The primary outcome measure was a combination of all-cause death, myocardial infarction (MI) and revascularisation with PCI. Angiographical outcome measures were in-stent restenosis (ISR) and stent thrombosis (ST). Results: Rates of the primary outcome measure for Xience and other DES were 31.9% and 28.2% respectively, adjusted hazard ratio (HR) 0.99 (95% CI 0.95–1.03). Crude rates of ISR were 2.9% versus 2.1% over 4.3 and 2.9 years respectively, adjusted HR 0.93 (95% CI 0.81–1.06). Crude rates of ST were 0.9% versus 0.7%, adjusted HR 1.07 (95% CI 0.82–1.39). Results were consistent in all sensitivity analyses. Conclusions: This nationally complete, real-world study confirms that Xience is a safe and effective DES with low-event rates of ISR and ST. Compared with a control group containing a large proportion of thinner strut stents and absorbable polymers, Xience exhibits similar results in all important clinical endpoints.
(Less)
- author
- Grimfjärd, Per ; Bergman, Elin ; Buccheri, Sergio ; Erlinge, David LU ; Lagerqvist, Bo ; Svennblad, Bodil ; Völz, Sebastian ; Angerås, Oskar and James, Stefan
- organization
- publishing date
- 2021
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- drug eluting stent, PCI, restenosis, stent thrombosis
- in
- Catheterization and Cardiovascular Interventions
- volume
- 98
- issue
- 2
- publisher
- Wiley-Blackwell
- external identifiers
-
- scopus:85102631520
- pmid:33719169
- ISSN
- 1522-1946
- DOI
- 10.1002/ccd.29641
- language
- English
- LU publication?
- yes
- id
- aed13f84-2aa1-4783-b227-4b58d6743004
- date added to LUP
- 2021-03-29 11:20:14
- date last changed
- 2024-09-22 16:54:48
@article{aed13f84-2aa1-4783-b227-4b58d6743004, abstract = {{<p>Objectives: To analyze the clinical outcome of percutaneous coronary intervention (PCI) using the Xience drug eluting stent (DES) versus other modern DES. Methods: This retrospective study based on the Swedish Coronary Angiography and Angioplasty Registry (SCAAR) analyzed the outcome of PCI using Xience versus other commonly used modern DES, 2007 to 2017. The primary outcome measure was a combination of all-cause death, myocardial infarction (MI) and revascularisation with PCI. Angiographical outcome measures were in-stent restenosis (ISR) and stent thrombosis (ST). Results: Rates of the primary outcome measure for Xience and other DES were 31.9% and 28.2% respectively, adjusted hazard ratio (HR) 0.99 (95% CI 0.95–1.03). Crude rates of ISR were 2.9% versus 2.1% over 4.3 and 2.9 years respectively, adjusted HR 0.93 (95% CI 0.81–1.06). Crude rates of ST were 0.9% versus 0.7%, adjusted HR 1.07 (95% CI 0.82–1.39). Results were consistent in all sensitivity analyses. Conclusions: This nationally complete, real-world study confirms that Xience is a safe and effective DES with low-event rates of ISR and ST. Compared with a control group containing a large proportion of thinner strut stents and absorbable polymers, Xience exhibits similar results in all important clinical endpoints.</p>}}, author = {{Grimfjärd, Per and Bergman, Elin and Buccheri, Sergio and Erlinge, David and Lagerqvist, Bo and Svennblad, Bodil and Völz, Sebastian and Angerås, Oskar and James, Stefan}}, issn = {{1522-1946}}, keywords = {{drug eluting stent; PCI; restenosis; stent thrombosis}}, language = {{eng}}, number = {{2}}, publisher = {{Wiley-Blackwell}}, series = {{Catheterization and Cardiovascular Interventions}}, title = {{Outcome of PCI with Xience versus other commonly used modern drug eluting stents : A SCAAR report}}, url = {{http://dx.doi.org/10.1002/ccd.29641}}, doi = {{10.1002/ccd.29641}}, volume = {{98}}, year = {{2021}}, }